AAP
TNXP icon

Arax Advisory Partners’s Tonix Pharmaceuticals TNXP Stock Holding History

Arax Advisory Partners’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$688 Buy
50
+38
+317% +$585 ﹤0.01% 3368
2025
Q4 		$187 Sell
12
-117
-91% -$2.16K ﹤0.01% 3733
2025
Q3 		$3.12K Buy
+129
New +$4.79K ﹤0.01% 3003

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Arax Advisory Partners's TNXP Position: Q1 2026 in Review

Arax Advisory Partners increased its Tonix Pharmaceuticals (TNXP) stake by 317% in Q1 2026, buying an estimated $585 and bringing the position to 50 shares worth $688. The position accounts for ﹤0.01% of the portfolio, ranked #3368.

Arax Advisory Partners first reported a position in TNXP in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.12K in Q3 2025. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Arax Advisory Partners held 50 shares of Tonix Pharmaceuticals worth $688 as of Q1 2026.
  • Arax Advisory Partners bought 38 Tonix Pharmaceuticals shares in Q1 2026, an estimated $585.
  • Tonix Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3368 holding.
  • Arax Advisory Partners first reported a position in Tonix Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Tonix Pharmaceuticals position peaked at $3.12K in Q3 2025.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.